Impact of hepatitis C virus polymorphisms on direct‐acting antiviral treatment efficacy: Regulatory analyses and perspectives
Patrick R. Harrington, Takashi E. Komatsu, Damon J. Deming, Eric F. Donaldson, Julian J. O'Rear, Lisa K. Naeger – 1 December 2017 – Several highly effective, interferon‐free, direct‐acting antiviral (DAA)‐based regimens are available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive efficacy overall, a small proportion of patients in registrational trials experienced treatment failure, which in some cases was associated with the detection of HCV resistance‐associated substitutions (RASs) at baseline.